Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants

Virgilio Carnielli, Giovanni Montini, Rosalia Da Riol, Roberto Dall'Amico, Felice Cantarutti

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

To determine whether prophylactic treatment with recombinant human erythropoietin (rHuEPO) and iron would reduce the need for blood transfusions, we randomly assigned 22 premature infants with gestational ages ≤32 weeks and birth weights ≤1.75 kg to receive rHuEPO, 400 IU/kg three times a week, plus iron, 20 mg/wk intravenously, from the second day of life (11 infants), or no rHuEPO and no iron (11 infants). The two groups had similar birth weights and clinical variables. The treated infants required fewer blood transfusions (0.8±1.5 vs 3.1±2.1; p=0.01) and less volume of packed erythrocytes (14.2±25.9 vs 48.4±34.0 ml/kg; p=0.02). The amounts of blood sampled were not different (19.5±21.1 vs 27.8±19.1 ml/kg; p=0.35). Reticulocyte and hematocrit values were higher in the treated group (4.46%±0.8% vs 1.49%±1.1% (p=0.0001) and 48.1%±7.3% vs 43.8%±4.7% (p=0.004), respectively). No side effects of either rHuEPO or intravenously administered iron were noted. These data indicate that rHuEPO, in combination with iron supplementation, is effective in reducing the need for blood transfusions in the premature infant. More information is needed on dosage, timing, and iron and vitamin supplementation.

Original languageEnglish
Pages (from-to)98-102
Number of pages5
JournalJournal of Pediatrics
Volume121
Issue number1
DOIs
Publication statusPublished - 1992

Fingerprint

Erythropoietin
Premature Infants
Blood Transfusion
Iron
Hematocrit
Birth Weight
Reticulocytes
Vitamins
Gestational Age

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. / Carnielli, Virgilio; Montini, Giovanni; Da Riol, Rosalia; Dall'Amico, Roberto; Cantarutti, Felice.

In: Journal of Pediatrics, Vol. 121, No. 1, 1992, p. 98-102.

Research output: Contribution to journalArticle

Carnielli, Virgilio ; Montini, Giovanni ; Da Riol, Rosalia ; Dall'Amico, Roberto ; Cantarutti, Felice. / Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. In: Journal of Pediatrics. 1992 ; Vol. 121, No. 1. pp. 98-102.
@article{c9435f55c2af43f9aab22a62a913d2ac,
title = "Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants",
abstract = "To determine whether prophylactic treatment with recombinant human erythropoietin (rHuEPO) and iron would reduce the need for blood transfusions, we randomly assigned 22 premature infants with gestational ages ≤32 weeks and birth weights ≤1.75 kg to receive rHuEPO, 400 IU/kg three times a week, plus iron, 20 mg/wk intravenously, from the second day of life (11 infants), or no rHuEPO and no iron (11 infants). The two groups had similar birth weights and clinical variables. The treated infants required fewer blood transfusions (0.8±1.5 vs 3.1±2.1; p=0.01) and less volume of packed erythrocytes (14.2±25.9 vs 48.4±34.0 ml/kg; p=0.02). The amounts of blood sampled were not different (19.5±21.1 vs 27.8±19.1 ml/kg; p=0.35). Reticulocyte and hematocrit values were higher in the treated group (4.46{\%}±0.8{\%} vs 1.49{\%}±1.1{\%} (p=0.0001) and 48.1{\%}±7.3{\%} vs 43.8{\%}±4.7{\%} (p=0.004), respectively). No side effects of either rHuEPO or intravenously administered iron were noted. These data indicate that rHuEPO, in combination with iron supplementation, is effective in reducing the need for blood transfusions in the premature infant. More information is needed on dosage, timing, and iron and vitamin supplementation.",
author = "Virgilio Carnielli and Giovanni Montini and {Da Riol}, Rosalia and Roberto Dall'Amico and Felice Cantarutti",
year = "1992",
doi = "10.1016/S0022-3476(05)82552-1",
language = "English",
volume = "121",
pages = "98--102",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants

AU - Carnielli, Virgilio

AU - Montini, Giovanni

AU - Da Riol, Rosalia

AU - Dall'Amico, Roberto

AU - Cantarutti, Felice

PY - 1992

Y1 - 1992

N2 - To determine whether prophylactic treatment with recombinant human erythropoietin (rHuEPO) and iron would reduce the need for blood transfusions, we randomly assigned 22 premature infants with gestational ages ≤32 weeks and birth weights ≤1.75 kg to receive rHuEPO, 400 IU/kg three times a week, plus iron, 20 mg/wk intravenously, from the second day of life (11 infants), or no rHuEPO and no iron (11 infants). The two groups had similar birth weights and clinical variables. The treated infants required fewer blood transfusions (0.8±1.5 vs 3.1±2.1; p=0.01) and less volume of packed erythrocytes (14.2±25.9 vs 48.4±34.0 ml/kg; p=0.02). The amounts of blood sampled were not different (19.5±21.1 vs 27.8±19.1 ml/kg; p=0.35). Reticulocyte and hematocrit values were higher in the treated group (4.46%±0.8% vs 1.49%±1.1% (p=0.0001) and 48.1%±7.3% vs 43.8%±4.7% (p=0.004), respectively). No side effects of either rHuEPO or intravenously administered iron were noted. These data indicate that rHuEPO, in combination with iron supplementation, is effective in reducing the need for blood transfusions in the premature infant. More information is needed on dosage, timing, and iron and vitamin supplementation.

AB - To determine whether prophylactic treatment with recombinant human erythropoietin (rHuEPO) and iron would reduce the need for blood transfusions, we randomly assigned 22 premature infants with gestational ages ≤32 weeks and birth weights ≤1.75 kg to receive rHuEPO, 400 IU/kg three times a week, plus iron, 20 mg/wk intravenously, from the second day of life (11 infants), or no rHuEPO and no iron (11 infants). The two groups had similar birth weights and clinical variables. The treated infants required fewer blood transfusions (0.8±1.5 vs 3.1±2.1; p=0.01) and less volume of packed erythrocytes (14.2±25.9 vs 48.4±34.0 ml/kg; p=0.02). The amounts of blood sampled were not different (19.5±21.1 vs 27.8±19.1 ml/kg; p=0.35). Reticulocyte and hematocrit values were higher in the treated group (4.46%±0.8% vs 1.49%±1.1% (p=0.0001) and 48.1%±7.3% vs 43.8%±4.7% (p=0.004), respectively). No side effects of either rHuEPO or intravenously administered iron were noted. These data indicate that rHuEPO, in combination with iron supplementation, is effective in reducing the need for blood transfusions in the premature infant. More information is needed on dosage, timing, and iron and vitamin supplementation.

UR - http://www.scopus.com/inward/record.url?scp=0026703752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026703752&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)82552-1

DO - 10.1016/S0022-3476(05)82552-1

M3 - Article

C2 - 1625101

AN - SCOPUS:0026703752

VL - 121

SP - 98

EP - 102

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -